Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk Journal Article


Authors: Villani, A.; Greer, M. L. C.; Kalish, J. M.; Nakagawara, A.; Nathanson, K. L.; Pajtler, K. W.; Pfister, S. M.; Walsh, M. F.; Wasserman, J. D.; Zelley, K.; Kratz, C. P.
Article Title: Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk
Abstract: In October 2016, the American Association for Cancer Research held a meeting of international childhood cancer predisposition syndrome experts to evaluate the current knowledge of these syndromes and to propose consensus surveillance recommendations. Herein, we summarize clinical and genetic aspects of RASopathies and Sotos, Weaver, Rubinstein-Taybi, Schinzel-Giedion, and NKX2-1 syndromes as well as specific metabolic disorders known to be associated with increased childhood cancer risk. In addition, the expert panel reviewed whether sufficient data exist to make a recommendation that all patients with these disorders be offered cancer surveillance. For all syndromes, the panel recommends increased awareness and prompt assessment of clinical symptoms. Patients with Costello syndrome have the highest cancer risk, and cancer surveillance should be considered. Regular physical examinations and complete blood counts can be performed in infants with Noonan syndrome if specific PTPN11 or KRAS mutations are present, and in patients with CBL syndrome. Also, the high brain tumor risk in patients with L-2 hydroxyglutaric aciduria may warrant regular screening with brain MRIs. For most syndromes, surveillance may be needed for nonmalignant health problems. ©2017 AACR.
Journal Title: Clinical Cancer Research
Volume: 23
Issue: 12
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2017-06-01
Start Page: e83
End Page: e90
Language: English
DOI: 10.1158/1078-0432.ccr-17-0631
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 3 July 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael Francis Walsh
    156 Walsh